Literature DB >> 29204737

Initial Slovenian experience with MitraClip therapy : Careful selection of patients is crucial for optimal outcome.

Jana Ambrožič1, Marta Cvijič2, Mojca Bervar2, Špela Mušič3, Matjaž Bunc2.   

Abstract

BACKGROUND: MitraClip is a percutaneous mitral repair technology increasingly used for high surgical risk patients with primary or secondary mitral regurgitation. We describe initial Slovenian experience with MitraClip and discuss the importance of identifying the suitable candidates for this procedure.
METHODS: We retrospectively analyzed the first 10 patients (mean age 75.6 ± 6.9 years, logistic Euroscore 28.4 ± 10.9%) with severe and moderate to severe mitral regurgitation (8 secondary, 1 primary and 1 mixed etiology) who underwent a MitraClip procedure between January 2015 and February 2017.
RESULTS: Acute reduction of mitral regurgitation was achieved in all but one patient (90%). There were no periprocedural mortalities and at short to mid-term follow-up (median 12 months, interquartile range 3-15 months). In eight patients improvement of functional class was observed at discharge. No functional improvement was achieved in a patient with advanced ischemic cardiomyopathy, and in a patient with degenerative mitral disease in whom the MitraClip procedure had failed necessitating mitral valve surgery. One patient experienced late leaflet detachment and was effectively managed with a second MitraClip procedure. There were two vascular complications at the access site and one percutaneous closure of an iatrogenic atrial septal defect.
CONCLUSION: Our initial experiences with a small number of patients indicate that percutaneous mitral repair with MitraClip is a feasible and safe method in high-risk patients. Special attention should be paid to careful patient selection including detailed echocardiographic evaluation of mitral valve anatomy, technical performance and final result, particularly at the beginning of the learning curve in order to reduce the rate of serious complications.

Entities:  

Keywords:  Echocardiography; MitraClip; Mitral anatomy; Mitral regurgitation; Percutaneous mitral valve repair

Mesh:

Year:  2017        PMID: 29204737     DOI: 10.1007/s00508-017-1295-7

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  24 in total

1.  Quantitation of mitral regurgitation after percutaneous MitraClip repair: comparison of Doppler echocardiography and cardiac magnetic resonance imaging.

Authors:  Christian Hamilton-Craig; Wendy Strugnell; Niranjan Gaikwad; Matthew Ischenko; Vicki Speranza; Jonathan Chan; Johanne Neill; David Platts; Gregory M Scalia; Darryl J Burstow; Darren L Walters
Journal:  Ann Cardiothorac Surg       Date:  2015-07

2.  Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy.

Authors:  Paul A Grayburn; Elyse Foster; Chithra Sangli; Neil J Weissman; Joseph Massaro; Donald G Glower; Ted Feldman; Laura Mauri
Journal:  Circulation       Date:  2013-09-06       Impact factor: 29.690

3.  Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system.

Authors:  Thomas Smith; Patrick McGinty; William Bommer; Reginald I Low; Scott Lim; Peter Fail; Jason H Rogers
Journal:  Catheter Cardiovasc Interv       Date:  2012-03-15       Impact factor: 2.692

4.  Diagnostic value of vena contracta area in the quantification of mitral regurgitation severity by color Doppler 3D echocardiography.

Authors:  Xin Zeng; Robert A Levine; Lanqi Hua; Eleanor L Morris; Yuejian Kang; Mary Flaherty; Nina V Morgan; Judy Hung
Journal:  Circ Cardiovasc Imaging       Date:  2011-07-05       Impact factor: 7.792

5.  2017 ESC/EACTS Guidelines for the management of valvular heart disease.

Authors:  Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2017-09-21       Impact factor: 29.983

6.  The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation.

Authors:  Jean-François Obadia; Xavier Armoiry; Bernard Iung; Thierry Lefèvre; Nathan Mewton; David Messika-Zeitoun; Bertrand Cormier; Julien Berthiller; Delphine Maucort-Boulch; Florent Boutitie; Bernadette Vaz; Jean-Noël Trochu; Alec Vahanian
Journal:  EuroIntervention       Date:  2015-03       Impact factor: 6.534

7.  Percutaneous edge-to-edge repair of mitral regurgitation as a bail-out strategy in critically ill patients.

Authors:  Sven T Pleger; Emmanuel Chorianopoulos; Ulrike Krumsdorf; Hugo A Katus; Raffi Bekeredjian
Journal:  J Invasive Cardiol       Date:  2013-02       Impact factor: 2.022

8.  Repeat MitraClip Therapy for Significant Recurrent Mitral Regurgitation in High Surgical Risk Patients: Impact of Loss of Leaflet Insertion.

Authors:  Felix Kreidel; Christian Frerker; Michael Schlüter; Hannes Alessandrini; Thomas Thielsen; Stephan Geidel; Ulrich Schäfer; Karl-Heinz Kuck
Journal:  JACC Cardiovasc Interv       Date:  2015-09       Impact factor: 11.195

Review 9.  Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging.

Authors:  Patrizio Lancellotti; Christophe Tribouilloy; Andreas Hagendorff; Bogdan A Popescu; Thor Edvardsen; Luc A Pierard; Luigi Badano; Jose L Zamorano
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2013-06-03       Impact factor: 6.875

10.  4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation.

Authors:  Laura Mauri; Elyse Foster; Donald D Glower; Patricia Apruzzese; Joseph M Massaro; Howard C Herrmann; James Hermiller; William Gray; Andrew Wang; Wesley R Pedersen; Tanvir Bajwa; John Lasala; Reginald Low; Paul Grayburn; Ted Feldman
Journal:  J Am Coll Cardiol       Date:  2013-05-09       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.